Edward R. Hammond
1 Westlink Court
Brisbane, QLD, Australia
Brisbane, QLD, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted α-Therapy for Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 27, 2025
An Enzymatic Activity Assay for Heparanase That Is Useful for Evaluating Clinically Relevant Inhibitors and Studying Kinetics.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: January 20, 2023
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Journal: Journal for immunotherapy of cancer
Published: December 14, 2022
Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain.
Journal: Computational and structural biotechnology journal
Published: January 25, 2021
Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
Journal: Advances in experimental medicine and biology
Published: April 11, 2020
Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.
Journal: Biochemical pharmacology
Published: January 30, 2020
Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Journal: Oncotarget
Published: October 15, 2019
The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Journal: Matrix biology : journal of the International Society for Matrix Biology
Published: April 23, 2018
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2018
Breast Cancer following Augmentation Mammaplasty: A Case-Control Study.
Journal: Plastic and reconstructive surgery
Published: March 30, 2018
Last Updated: 09/26/2026